ha14-1 has been researched along with Osteogenic Sarcoma in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baranski, Z | 1 |
| de Jong, Y | 1 |
| Ilkova, T | 1 |
| Peterse, EF | 1 |
| Cleton-Jansen, AM | 1 |
| van de Water, B | 1 |
| Hogendoorn, PC | 1 |
| Bovée, JV | 1 |
| Danen, EH | 1 |
1 other study available for ha14-1 and Osteogenic Sarcoma
| Article | Year |
|---|---|
Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzopyrans; Biphenyl Comp | 2015 |